SCHEMBL19299652

SCHEMBL19299652

CCCOc1ccc(C(=O)NNC(=S)NC(=O)c2ccco2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 1.00
KDM4E B2RXH2 8/20 1.00
HTT P42858 7/20 0.73
GAA P10253 5/20 0.73
SMN1; SMN2 Q16637 3/20 0.73
CYP2C9 P11712 1/20 0.73
RECQL P46063 1/20 0.73
KMT2A Q03164 8/20 0.71
MEN1 O00255 5/20 0.71
POLB P06746 1/20 0.71
LMNA P02545 3/20 0.67
CRHBP P24387 1/20 0.67
CRHR2 Q13324 1/20 0.67
AGTR1 P30556 1/20 0.66
CYP2C19 P33261 1/20 0.66
OPRK1 P41145 1/20 0.66
UBE2N P61088 1/20 0.66
ALDH1A1 P00352 2/20 0.66
TDP1 Q9NUW8 1/20 0.66
NLRP1 Q9C000 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19299715 0.89 KDM4E (0.82) MAPTKDM4EHTTGAASMN1; SMN2
SCHEMBL19294511 0.86 MAPT (0.75) MAPTKDM4EHTTGAASMN1; SMN2
SCHEMBL19294486 0.85 MAPT (1.00) MAPTKDM4EHTTGAASMN1; SMN2
SCHEMBL19294509 0.81 LMNA (0.74) MAPTKDM4EHTTGAASMN1; SMN2
SCHEMBL19299516 0.81 KDM4E (1.00) MAPTKDM4EHTTGAASMN1; SMN2
SCHEMBL19299372 0.80 KMT2A (1.00) MAPTKDM4EHTTGAASMN1; SMN2
SCHEMBL19299656 0.80 KDM4E (0.82) MAPTKDM4EHTTGAASMN1; SMN2
SCHEMBL19294541 0.79 KDM4E (0.80) MAPTKDM4EHTTGAASMN1; SMN2
SCHEMBL19299521 0.79 KDM4E (1.00) MAPTKDM4EHTTGAASMN1; SMN2
SCHEMBL19299695 0.78 KDM4E (1.00) MAPTKDM4EHTTGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3212183-B1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS UNIV ROCHESTER (US) 2019-10-02 EP disclosed
US-10028931-B2 Synergistic compositions for treating microbial infections UNIVERSITY OF ROCHESTER (US) 2018-07-24 US disclosed
US-20170246139-A1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS UNIVERSITY OF ROCHESTER (US) 2017-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10028931-B2 Synergistic compositions for treating microbial infections RNASE1, RNASEL, RNASEH1 MAPT 4406/4885KDM4E 2925/4885HTT 3136/4885
US-20170246139-A1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS RNASE1, RNASEL, RNASEH1 MAPT 4406/4885KDM4E 2925/4885HTT 3136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.